Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin - Seite 2

Pierre-Alain Ruffieux, CEO, Lonza, commented: “We are pleased to have maintained a solid financial performance in H1 2022, thanks to the commitment and support of Lonza’s global employee community. As part of our planned CAPEX for the year, we have announced a landmark strategic investment in Biologics to build a new commercial fill and finish facility in Stein (CH). This will help us to meet customer demand for an integrated offering and deliver long-term value to our business. Looking at our macroeconomic context, we remain aware of the continuing uncertainties and will actively manage any issues that may arise.”

Divisional Overview

• Biologics benefited from continued strong customer demand for commercial capacity, supported by new CAPEX investments. Compared to Half-Year 2021, the business achieved 26.2%¹ sales growth, with a lower CORE EBITDA margin of 37.3%. The softer margin reflected the product mix. 
• Small Molecules successfully executed capacity expansions in Nansha (CN), Tampa (US) and Bend (US). Continued momentum in customer signings supports long-term success. The division delivered lower sales caused by the phasing of major shipments to contracted customers. CORE EBITDA margin increased 2.6ppts to 29.9% compared to Half-Year 2021, supported by growth projects, high utilization and portfolio mix.
• Cell & Gene saw strong customer demand for Bioscience products. In Cell and Gene Technologies, there was a continued focus on the scale-up of late-stage products. The commercialization of Cocoon remains on track. Including a one-time event, the division saw 23.4%¹ sales growth and a margin increase of 6.3ppts to 22.4%, compared to Half-Year 2021. Excluding the one-time event, margin remained broadly stable compared to Half-Year 2021.
• Capsules & Health Ingredients saw the market continuing to shift towards high growth area of specialty capsules and delivered a stable CORE EBITDA margin of 35.2% compared to Half-Year 2021, accompanied by positive sales growth. The business is on track to deliver a 260 billion annualized capsule capacity by the end of 2022.

Group Financial Summary